RCBTB2

RCBTB2 (CHC1L) is a multi-domain protein that combines an N-terminal RCC1-like seven-bladed repeat region with a C-terminal BTB domain, acting both as a regulator of microtubule-organizing-center function and as a tumor suppressor (PMID:9806834, PMID:26291700). Through its BTB domain it is directed to vesicular and perinuclear compartments, and it localizes to Golgi bodies and centrosomes where it is required for primary cilium formation: loss of RCBTB2 reduces ciliogenesis and shortens cilia, a defect reversed by re-expression, consistent with a role in cargo transport from Golgi to centrosome (PMID:22768142, PMID:25762510). RCBTB2 functions as a ubiquitin ligase, directly binding GPAA1 and driving its ubiquitin-mediated proteasomal degradation, and its overexpression suppresses prostate cancer cell proliferation, migration, invasion, epithelial-mesenchymal transition, and xenograft growth (PMID:41244118). Consistent with a tumor-suppressive role, Chc1L-knockout mice develop histiocytic sarcoma, and reduced expression of its 551-amino-acid isoform is seen in prostate cancer (PMID:12115502, PMID:26291700). The catalytic basis of its inferred RCC1-like GEF activity has not been directly demonstrated in the available corpus.

1. 1998 Medium

   Establishing the gene's domain architecture answered what protein family RCBTB2 belongs to, predicting a guanine-nucleotide-exchange-related function from its RCC1 homology.

   Evidence cDNA cloning, genomic characterization, and sequence homology analysis mapping the gene to 13q14.3

   PMID:9806834

   Open questions at the time

   • GEF activity inferred from homology, never demonstrated biochemically
   • No substrate GTPase identified
   • Function of the C-terminal region not addressed
2. 2002 Medium

   Isoform-resolved expression profiling addressed which RCBTB2 product is dysregulated in cancer, linking specific loss of the 551 aa isoform to prostate tumors.

   Evidence Quantitative RT-PCR isoform analysis in primary prostate tumors vs. normal tissue

   PMID:12115502

   Open questions at the time

   • Correlation only; no causal mechanism for tumor suppression shown
   • Functional difference between the 551 and 526 aa isoforms unknown
3. 2012 Medium

   Domain-dissection localization studies answered how RCBTB2 is targeted within the cell, showing the BTB domain rather than the RCC1 region directs subcellular localization, and placed the protein at the acrosome during spermatogenesis.

   Evidence Immunofluorescence co-localization with acrosomal markers and GFP-tagged domain constructs in transfected CHO cells

   PMID:22768142

   Open questions at the time

   • Molecular basis of BTB-mediated targeting not defined
   • Acrosomal function not tested by loss-of-function
   • Done in mouse ortholog and CHO cells
4. 2015 High

   Loss-of-function with rescue answered whether RCBTB2 has a cellular role at the centrosome, establishing it as a necessary component of primary cilium formation.

   Evidence Stable shRNA knockdown, Golgi/centrosome immunolocalization, cilia length measurement, and rescue by re-expression in NIH3T3 and IMCD3 cells

   PMID:25762510

   Open questions at the time

   • Proposed Golgi-to-centrosome cargo transport mechanism not directly demonstrated
   • No identified ciliary cargo or transport machinery partner
5. 2015 High

   A whole-animal knockout addressed whether RCBTB2 is a tumor suppressor in vivo, demonstrating that its loss drives histiocyte proliferation and neoplasia.

   Evidence Chc1L knockout mouse with histopathology and ex vivo proliferation assays of bone marrow and spleen cells

   PMID:26291700

   Open questions at the time

   • Molecular pathway linking loss to histiocyte proliferation not defined
   • Tumor-suppressor mechanism not connected to ciliary or ubiquitin functions
6. 2015 Low

   A reported interaction placed RCBTB2 in a spermiogenesis signaling pathway, naming SPAG16S as a partner relevant to flagella and cilia formation.

   Evidence Binding-partner identification cited within the ciliogenesis study

   PMID:25762510

   Open questions at the time

   • Specific binding assay not detailed; single reference point
   • Functional consequence of the interaction not tested
   • No reciprocal validation
7. 2023 Low

   Tumor-versus-normal localization scoring addressed where RCBTB2 normally acts, indicating predominantly nuclear localization that is lost with plasma-membrane mislocalization in oral squamous cell carcinoma.

   Evidence Quantitative immunohistochemical subcellular localization scoring in OSCC vs. normal oral mucosa

   PMID:37311552

   Open questions at the time

   • Descriptive IHC only; no functional consequence demonstrated
   • Nuclear function of RCBTB2 not characterized
   • Inconsistent with Golgi/centrosome localization reported elsewhere; not reconciled
8. 2025 High

   Identification of an enzymatic activity and substrate answered how RCBTB2 suppresses tumor progression at the molecular level, showing it is a ubiquitin ligase that degrades GPAA1.

   Evidence RCBTB2 overexpression, Co-IP, co-localization, protein-but-not-mRNA downregulation of GPAA1, proliferation/migration/invasion assays, GPAA1 knockdown, and a nude-mouse xenograft model

   PMID:41244118

   Open questions at the time

   • E3 ligase catalytic machinery and ubiquitination site not defined
   • Relationship between ligase activity and the RCC1/BTB domains unresolved
   • Connection to ciliary and tumor-suppressor phenotypes not integrated

• How RCBTB2's distinct activities — RCC1-like domain, BTB-mediated localization, ciliogenesis, and GPAA1-directed ubiquitin ligase function — mechanistically integrate into a single tumor-suppressive program remains unresolved.
• No direct demonstration of RCC1-like GEF activity or a target GTPase
• Structural basis of substrate recognition by the ligase unknown
• Conflicting subcellular localization reports (nuclear vs. Golgi/centrosome) not reconciled